Guidelines reflecting contemporary clinical practice in the management of Buruli ulcer (Mycobacterium ulcerans infection) in Australia were published in 2007.
Management has continued to evolve, as new evidence has become available from randomised trials, case series and increasing clinical experience with oral antibiotic therapy.
Therefore, guidelines on the diagnosis, treatment and prevention of Buruli ulcer in Australia have been updated. They include guidance on the new role of antibiotics as first-line therapy; the shortened duration of antibiotic treatment and the use of all-oral antibiotic regimens; the continued importance, timing and role of surgery; the recognition and management of paradoxical reactions during antibiotic treatment; and updates on the prevention of disease.
- 1. Johnson PD, Stinear T, Small PL, et al. Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLOS Med 2005; 2: e108.
- 2. George KM, Chatterjee D, Gunawardana G, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999; 283: 854-857.
- 3. Boyd SC, Athan E, Friedman ND, et al. Epidemiology, clinical features and diagnosis of Mycobacterium ulcerans in an Australian population. Med J Aust 2012; 196: 341-344. <MJA full text>
- 4. Jenkin GA, Smith M, Fairley M, Johnson PD. Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland. Med J Aust 2002; 176: 180-181. <MJA full text>
- 5. Steffen CM, Smith M, McBride WJ. Mycobacterium ulcerans infection in North Queensland: the ‘Daintree ulcer’. ANZ J Surg 2010; 80: 732-736.
- 6. Francis G, Whitby M, Woods M. Mycobacterium ulcerans infection: a rediscovered focus in the Capricorn Coast region of central Queensland. Med J Aust 2006; 185: 179-180. <MJA full text>
- 7. Quinn JV, Crotty JM. Mycobacterium ulcerans infections in the Northern Territory. Med J Aust 1963; 2: 317-319.
- 8. Johnson PD, Hayman JA, Quek TY, et al. Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Med J Aust 2007; 186: 64-68. <MJA full text>
- 9. O’Brien DP, Hughes AJ, Cheng AC, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007; 186: 58-61. <MJA full text>
- 10. Bentoucha A, Robert J, Dega H, et al. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2001; 45: 3109-3112.
- 11. Ji B, Chauffour A, Robert J, et al. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2007; 51: 3737-3739.
- 12. Ji B, Lefrançois S, Robert J, et al. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 2006; 50: 1921-1926.
- 13. Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005; 49: 3182-3186.
- 14. Gordon CL, Buntine JA, Hayman JA, et al. All-oral antibiotic treatment for buruli ulcer: a report of four patients. PLOS Negl Trop Dis 2010; 4: e770.
- 15. O’Brien DP, McDonald A, Callan P, et al. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLOS Negl Trop Dis 2012; 6: e1473.
- 16. Friedman ND, Athan E, Hughes AJ, et al. Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort. PLOS Negl Trop Dis 2013; 7: e2315.
- 17. Ross BC, Marino L, Oppedisano F, et al. Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol 1997; 35: 1696-1700.
- 18. Yeboah-Manu D, Danso E, Ampah K, et al. Isolation of Mycobacterium ulcerans from swab and fine-needle-aspiration specimens. J Clin Microbiol 2011; 49: 1997-1999.
- 19. Nienhuis WA, Stienstra Y, Thompson WA, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010; 375: 664-672.
- 20. Chauty A, Ardant MF, Adeye A, et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 2007; 51: 4029-4035.
- 21. Sarfo FS, Phillips R, Asiedu K, et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 2010; 54: 3678-3685.
- 22. Chauty A, Ardant MF, Marsollier L, et al. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis 2011; 52: 94-96.
- 23. World Health Organization. Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers. Geneva: WHO, 2012.
- 24. Thangaraj HS, Adjei O, Allen BW, et al. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J Antimicrob Chemother 2000; 45: 231-233.
- 25. Saito H, Ishii N. Antibacterial activities of new fluoroquinolones against Mycobacterium ulcerans. J Antimicrob Chemother 2001; 47 Suppl 1: 30.
- 26. O’Brien DP, Athan E, Hughes A, Johnson PD. Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report. J Med Case Rep 2008; 2: 123.
- 27. Yoshida K, Yabe K, Nishida S, et al. Pharmacokinetic disposition and arthropathic potential of oral ofloxacin in dogs. J Vet Pharmacol Ther 1998; 21: 128-132.
- 28. Zimbabwe, Bangladesh, South Africa (Zimbasa) Dysentery Study Group. Multicenter, randomized, double blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children. Pediatr Infect Dis J 2002; 21: 1136-1141.
- 29. Simpson C, O’Brien DP, McDonald A, Callan P. Mycobacterium ulcerans infection: evolution in clinical management. ANZ J Surg 2013; 83: 523-526.
- 30. O’Brien DP, Walton A, Hughes AJ, et al. Risk factors for recurrent Mycobacterium ulcerans disease after exclusive surgical treatment in an Australian cohort. Med J Aust 2013; 198: 436-439. <MJA full text>
- 31. Nienhuis WA, Stienstra Y, Abass KM, et al. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis 2012; 54: 519-526.
- 32. O’Brien DP, Robson M, Friedman ND, et al. Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC Infect Dis 2013; 13: 416.
- 33. Ruf MT, Chauty A, Adeye A, et al. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLOS Negl Trop Dis 2011; 5: e1252.
- 34. O’Brien DP, Robson ME, Callan PP, McDonald AH. “Paradoxical” immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 2009; 191: 564-566. <MJA full text>
- 35. Friedman ND, McDonald AH, Robson ME, O’Brien DP. Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans. PLOS Negl Trop Dis 2012; 6: e1767.
- 36. Trevillyan JM, Johnson PD. Steroids control paradoxical worsening of Mycobacterium ulcerans infection following initiation of antibiotic therapy. Med J Aust 2013; 198: 443-444. <MJA full text>
- 37. Junghanss T, Um Boock A, Vogel M, et al. Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLOS Negl Trop Dis 2009; 3: e380.
- 38. Johnson PD, Azuolas J, Lavender CJ, et al. Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis 2007; 13: 1653-1660.
- 39. Quek TY, Henry MJ, Pasco JA, et al. Mycobacterium ulcerans infection: factors influencing diagnostic delay. Med J Aust 2007; 187: 561-563. <MJA full text>
- 40. Johnson PD, Lavender CJ. Correlation between Buruli ulcer and vector-borne notifiable diseases, Victoria, Australia. Emerg Infect Dis 2009; 15: 614-615.
- 41. Fyfe JA, Lavender CJ, Handasyde KA, et al. A major role for mammals in the ecology of Mycobacterium ulcerans. PLOS Negl Trop Dis 2010; 4: e791.
- 42. Pouillot R, Matias G, Wondje CM, et al. Risk factors for buruli ulcer: a case control study in Cameroon. PLOS Negl Trop Dis 2007; 1: e101.
- 43. Landier J, Boisier P, Fotso Piam F, et al. Adequate wound care and use of bed nets as protective factors against Buruli ulcer: results from a case control study in Cameroon. PLOS Negl Trop Dis 2011; 5: e1392.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.